Mediomics, LLC, (Limited Liability Corporation) was founded and registered in the State of Missouri by Professor Yie-Hwa Chang in 2001. The company exclusively licensed worldwide commercial development rights of proprietary technologies developed in the laboratories of Professor Yie-Hwa Chang, Ph.D. and Professor Tomasz Heyduk, Ph.D. at the Saint Louis University School of Medicine in St. Louis, Missouri, as well as technology developed in the laboratory of Professor David M. Waisman, Ph.D., at the University of Calgary School of Medicine, in Alberta, Canada. Two of these technologies, one developed in Dr. Chang¡¯s laboratory and the other developed in laboratory of Dr. Waisman, relate to different anti-angiogenesis therapeutic compositions. The technology developed in the laboratory of Dr. Heyduk relates to a novel assay platform which will be used in the development of in vitro assays for easily and reliably measuring of the activity of DNA-binding proteins and their co-regulators (ligands).